Myeloma
The latest news, research, and perspectives in multiple myeloma. Myeloma is a hematologic malignancy characterized by the proliferation of malignant plasma cells that produce monoclonal immunoglobulin. These neoplastic cells result in characteristic clinical features that include bone lytic lesions, hypercalcemia, renal insufficiency, and anemia.
Advertisement
Advertisement
Experts call for rethinking smoldering myeloma as a distinct disease, with new data supporting early risk-based intervention.
Experts discuss the link between dietary patterns and blood cancer risk and the shortcomings of epidemiological studies.
LucyRx’s pharmacy network includes Northwestern Medicine Specialty Pharmacy, Dana Farber Cancer Institute, and more..
The agent is designed to be an option for cases where CAR T-cell therapies or first-generation bispecifics are unsuccessful.
In the US, a BLA submitted for these two particular combinations is currently under review at the FDA.
Phase 1b data suggest that continuous low-dose lenalidomide improves the therapeutic index in patients RRMM.
Gurbakhash Kaur, MD joins the host of The HemOnc Pulse Live! for a comprehensive discussion about the RedirecT-1 trial.
ISB 2001, a novel BCMA-targeting trispecific antibody, showed increased expression of T-cell activation cell surface markers.
A QSP model of ISB 2001, a novel trispecific antibody, offers an effective pathway for designing phase 1 studies.
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
Dr. Parekh discussed the promising future of trispecifics, the group of patients with the largest unmet need, and more.
Investigators assert clinical trial design features may have contributed to this antibody-drug conjugate's loss of approvals.
Samir Parekh, MD, Appointed Director of the Center of Excellence for Multiple Myeloma at Mount Sinai
Dr. Parekh’s laboratory focuses on developing personalized treatment strategies for patients with multiple myeloma.
Seta Degann, MD, resident physician at George Washington University, described the challenges of diagnosing younger patients.
More than 240 meetings were held with members of Congress as part of the ASCO 10th Annual Advocacy Summit.
Dr. Shah discusses the significance and limitations of two studies on dietary factors and risk of myeloma and MGUS.
A plant-based diet is significantly associated with a reduced risk of multiple myeloma.
Dr. Richard shares her passion for cellular therapy, how her mother’s leukemia diagnosis shaped her career, and more.
A US population-based study investigated the associations between MGUS and various dietary patterns.
The experts focused on cilta-cel when comparing the three FDA-approved treatments' efficacies, toxicities, and availability.
CAR T-cell therapy had the best OS and PFS, with BCMA-directed therapies also showing high rates of response.
This myeloma awareness month, clinicians are pushing for new treatment options to accelerate the journey towards a cure.
Within the first cycle of daratumumab-based therapy, all patients achieved serum free light chain reduction of 50% or more.
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
A study finds shortened overall survival with thrombotic events more severe in arterial thrombosis than venous thrombosis.
This orally available, selective inhibitor of XPO1 is the first agent of its kind to receive commercialization approval.
BCMA–directed CAR Ts were a vital advancement to RRMM treatment. Now, oncologists wonder which agent works best.
The CARTITUDE-4, KarMMa-3, and DREAMM-7 trials are paving the way for immunotherapy in multiple myeloma.
Do IMID-containing quadruplet therapies represent both the present and future of myeloma treatment?
Linvoseltamab continues to be clinically evaluated as monotherapy and in combination therapy for relapsed or refractory MM.
Lenalidomide is indicated to treat myeloma in combination with dexamethasone and transfusion-dependent anemia due to MDS.
A retrospective study supported the safety of teclistamab and demonstrated a PFS benefit for patients with advanced myeloma.
A first-in-human multicenter phase I trial of this oral agent for relapsed or refractory disease is in progress.
Michael Tomasson, MD, discusses combining elranatamab with carfilzomib and dexamethasone in multiple myeloma.
Based on LINKER-MM1, FDA approval for linvoseltamab is under consideration.
Dr. Cole spoke about becoming an oncologist, his commitment to mitigating disparities for Black patients with MM, and more.
Blood Cancers Today spoke with several clinicians about how quadruplets are changing the myeloma treatment landscape.
Dr. Rakesh Popat joins the hosts of “Blood Cancer Talks” to highlight myeloma research presented at ASH 2024.
Dr. Patel discusses PFS and MRD negativity results from the CARTITUDE-4 trial of cilta-cel versus standard of care in MM.
The single-slide test helps clinicians differentiate more than 60 subtypes of these diseases from normal immune response.
Equecabtagene autoleucel demonstrated early, deep, and durable responses with manageable safety in the FUMANBA-1 trial.
Dr. Callander discusses a study on selinexor, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
Patient-reported outcomes of the CARTITUDE-4 trial showed an improvement in quality of life with cilta-cel versus SOC.
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
An expert on site at ASH 2024 discusses the MRD negativity data from CARTITUDE-4.
Noa Biran, MD reviews a clinical trial of SPd for relapsed or refractory multiple myeloma.
Rahul Banerjee, MD, of the Fred Hutchinson Cancer Center, discusses notable studies in myeloma presented at ASH 2024.
Ide-cel demonstrated similar outcomes and toxicities among patients 70 years and older compared with younger patients.
Ide-cel achieved a CR rate of 80.6%, an ORR of 87.1%, and a MRD negativity rate of 66.7% in patients with myeloma.
A study stresses psychological support as an essential component of comprehensive cancer care.
The group discussed four abstracts on belantamab mafodotin in MM presented at EHA 2024 and ASCO 2024.
The interest in using quantitative tests to measure residual cancer cells continues to expand in the arena of blood cancers.
A study demonstrated favorable outcomes among high-risk patients with newly diagnosed MM who received HSCT consolidation.
Cilta-cel plus lenalidomide maintenance provides deep and durable responses with no new safety signals in patients with MM.
Daratumumab-based induction therapy showed improved responses and comparable safety in newly diagnosed multiple myeloma.
Adding isatuximab to standard-of-care improved CR and MRD negativity rates in transplant-eligible, newly diagnosed MM.
A retrospective study highlighted differences in infection rates and healthcare utilization following CAR-T therapy.
Mezigdomide, tazemetostat, and dexamethasone demonstrated promising efficacy and safety in relapsed or refractory MM.
A phase II trial in patients with at least three prior treatments evaluated two target doses of the CAR T-cell therapy.
This real-world study characterized step-up dosing models for talquetamab in patients with multiple myeloma.
Talquetamab and pomalidomide induced rapid and deep responses in patients with relapsed or refractory multiple myeloma.
The iMMagine-3 randomized trial has begun enrollment of patients with relapsed or refractory multiple myeloma.
OS, infections, hospitalization, and availability off the shelf were preferred treatment attributes of T-cell engagers.
The agent is newly approved in polytherapy with bortezomib and dexamethasone for multiple myeloma in adults.
Dr. Atrash reviews real-world data on four selinexor-based triplets used in the treatment of relapsed or refractory myeloma.
Drs. Rossi and Khouri discuss two presentations on the effects of selinexor exposure on CAR-T outcomes in multiple myeloma.
The agent is a first-of-its-kind, orally available, selective inhibitor of the nuclear export protein exportin 1.
The new indication for daratumumab and hyaluronidase-fihj plus D-VRd is based on results from the phase II CEPHEUS study.
MRD negativity is a strong predictor of better prognosis and survival in patients with MM.
Ongoing detection of TP53 mutations remains critical for accurate risk stratification and treatment planning in MM.
Patients with double-hit or triple-hit MM had significantly poorer outcomes compared to those with single-hit MM.
Novel agents such as belantamab mafodotin may improve PFS in patients with relapsed MM after anti-CD38 treatment.
Anito-cel showed "robust" efficacy in patients with relapsed or refractory multiple myeloma.
Myeloma in remission did not appear to affect myocardial infarction outcomes, but did affect resource utilization.
The latest data update on teclistamab in multiple myeloma continues to support strong efficacy and durable response.
The addition of daratumumab improved the performance of VRd in patients with newly diagnosed multiple myeloma.
The bispecific antibody was administered as a fourth-line treatment 12 years after the patient’s diagnosis.
Prior to the retrospective study presented at SOHO 2024, no study conducted a similar comparison of Dara-VTD and RVD.
The phase III KarMMa-9 trial will review the efficacy of R maintenance alone versus with ide-cel in newly diagnosed MM.
Prior research suggested that weekly carfilzomib at a dose of 70 mg/m2 plus dexamethasone can increase PFS.
The addition of daratumumab to VRd induction and consolidation induced higher rates of MRD negativity.
A single tocilizumab dose prior to initiation of teclistamab therapy effectively reduced the incidence of CRS.
Treatment with CELMoDs showed promising efficacy but high rates of neutropenia in patients with multiple myeloma.
Cilta-cel improved outcomes versus standard or care in myeloma, with a safety profile consistent with CAR-T therapies.
“Blood Cancer Talks" hosts are joined by Timothy Schmidt, MD, to discuss quadruplet therapy for myeloma.
Patients in the cohort of a post-hoc analysis of the phase III CARTITUDE-4 trial received two different bridging regimens.
A retrospective study compared results from daratumumab plus carfilzomib plus dexamethasone in different lines of therapy.
Patients in the trial subanalysis had previously received an immunomodulatory agent, proteasome inhibitor, and daratumumab.
The review also compiled an array of proposed solutions to meet the needs of patients and caregivers.
Myeloma experts are advocating for dose reductions of bortezomib due to improved safety and comparable efficacy.
The approval is based on results from the PERSEUS trial, in which D-VRd achieved deeper responses when compared with VRd.
Dr. Martin highlighted research in quadruplet therapy, CAR-T therapy, and bispecific T-cell engagers.
A triplet for multiple myeloma has shown promising safety and efficacy in elderly patients ineligible for transplant.
Linvoseltamab achieved on ORR of 71% and a CR rate of 50% in patients with relapsed or refractory multiple myeloma.
James Berenson, MD, of the Berenson Cancer Center, discusses the launch of the Myeloma BioBank.
Dr. Manier tells of which new phase III data he finds especially exciting in myeloma care.
Ola Landgren, MD, PhD, discusses three studies on quadruplet therapy presented at the 2024 ASCO Annual Meeting.
Dr. Costa presents subgroup findings from the single-line therapy patients in the CARTITUDE-4 phase III trial.
Drs. Hira Mian and Manni Mohyuddin join the hosts of "Blood Cancer Talks" for an overview of myeloma maintenance therapy.
Cilta-cel is now indicated for adult patients who have received at least one prior line of therapy.
Donna Catamero, ANP-BC, OCN, CCRC, discusses selinexor for myeloma, the BOSTON trial, and other recent advances in myeloma.
The FDA ODAC voted in favor of the use of MRD-negativity as an intermediate endpoint for accelerated approval in MM trials.
The “real revolution” in myeloma is in the immune therapies, Dr. Anderson said, such as bispecific T-cell engagers and ...
The overall response rate was 71%, and the most common side effects were CRS, neutropenia, and anemia.
Cilta-cel was previously approved by the FDA in relapsed or refractory MM after four or more prior lines of therapy.
The expansion of the indication was supported by positive data from the KarMMa-3 study.
KarMMa-3 trial evaluated ide-cel in MM, while the CARTITUDE-4 trial evaluated cilta-cel in MM.
The approval was based on results from the KarMMa-3 study, which compared ide-cel with standard combination regimens.
The 11-member panel of independent experts voted eight in favor and three against.
The FDA Oncologic Drugs Advisory Committee voted to recommend approval of the supplemental BLA for cilta-cel in myeloma.
For Dr. Banerjee, this month is a call to action to mitigate global disparities in myeloma treatment.
S. Vincent Rajkumar, MD, a myeloma clinician and researcher, currently serves as a Professor of Medicine at the Mayo Clinic.
Sebia’s free light chain (FLC) kappa and lambda assays have 510(k) clearance.
A phase I clinical trial on IDP-023 is currently enrolling patients.
The target action date for the FDA’s decision is August 22, 2024.
Adding elotuzumab to induction, consolidation, or maintenance treatment did not result in improved PFS or OS.
The study used public data from various online sources related to approved CAR-T therapies for MM.
The sBLA was approved for a reduced dosing frequency of 1.5 mg/kg every two weeks in relapsed or refractory myeloma.
The mandate could affect moving CAR-T therapies into earlier lines of therapy for multiple myeloma.
The addition of daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy improved PFS.
Belamaf, bortezomib, and dexamethasone improved survival versus daratumumab bortezomib, and dexamethasone in myeloma.
Adding daratumumab and hyaluronidase-fihj to lenalidomide, bortezomib and dexamethasone reduced the risk of progression.
Researchers are working to define and validate the ways in which mass spectrometry can aid in MM diagnosis and monitoring.
The Marketing Authorization Application for linvoseltamab has been submitted and is under review by the EMA.
A higher percentage of patients receiving daratumumab achieved negative MRD compared with patients who did not.
Drs. Saurabh Dahiya and Jay Spiegel stop by The HemOnc Pulse to discuss the recent news on CAR-T therapies and the FDA.
The CHMP of the European Medicines Agency gave a positive recommendation for the Marketing Authorization approval of ide-cel.
The agency's statement follows potential risks identified by the FDA Adverse Event Reporting System.
The study aimed to describe the myeloma-defining events and clinical presentations leading to multiple myeloma diagnosis.
Sanjay Patel, MD, discusses a study on spatial mapping of human hematopoiesis using bone marrow tissue.
The study also identified 12 distinct subtypes of myeloma, expanding on previous classifications.
Paula Rodríguez Otero, MD, described an updated analysis of the KarMMa-3 trial presented at the 65th ASH Annual Meeting.
Physician Assistant Dwight Macero, one of the clinical consultants on the survey, offers his thoughts on the results.
Dr. Derman and the hosts discuss myeloma abstracts from ASH 2023, including the PERSEUS trial and the KarMMa-3 trial.
Leyla Shune, MD, discusses the import of promising data for ide-cel in multiple myeloma presented at the 2023 ASH Meeting.
Dr. Ghobrial discusses how she entered the field of smoldering myeloma, the racial gap in myeloma research, and more.
Dr. Fonseca, of the Mayo Clinic, spoke with Blood Cancers Today about idecabtagene vicleucel in myeloma treatment.
Elranatamab yielded deep and durable responses in relapsed or refractory multiple myeloma, even with biweekly dosing.
Dara-CVRd was effective as induction therapy prior to and consolidation therapy following AHSCT in ultra-high-risk myeloma.
Motixafortide plus G-CSF mobilized significantly more CD34+ hematopoietic stem and progenitor cells versus placebo in MM.
Dr. Usmani shares insights on the evolution in myeloma treatment since he first started practicing.
Dr. Hans Lee met with Blood Cancers Today to discuss outcomes and treatments after triple-class exposure in multiple myeloma.
The study compared characteristics, step up dosing process, and incidence and management of cytokine release syndrome.
Dr. Mikhael reflected on how the BOSTON and STOMP studies impacted the myeloma treatment paradigm.
Drs. Lonial, Nabhan, and Stewart discussed the plenary session at ASH, the PERSEUS trial, and treating smoldering MM.
Dr. Raje shared findings on CAR T-cell therapy in earlier lines of treatment for relapsed or refractory multiple myeloma.
Hamza Hashmi, MD, discusses his research at ASH 2023 and whether the results would affect the way he treats elderly patients.
Dr. Raje discussed the Perseus trial, in which most patients were progression-free at four years after a four-drug regimen.
Patients with lenalidomide-refractory MM had significant improvements in health-related QoL and symptoms after cilta-cel.
Cilta-cel was significantly more cost-effective versus DPd or PVd regimens in relapsed or refractory multiple myeloma.
Jeffrey Matous, MD, discusses data from the phase Ib MonumenTAL-2 study on talquetamab plus pomalidomide in multiple myeloma.
Ajai Chari, MD, described findings from the MonumenTAL-1 study on talquetamab in patients with myeloma.
The study included 84 patients with MM who had a median of four prior lines of therapy.
CAR-T therapy, while complex and expensive, has better PFS than autologous or allogenic stem cell transplantation.
Dr. Al-Ola Abdallah, of the University of Kansas, covers important multiple myeloma data presented at the 2023 ASH meeting.
Doris Hansen, MD, discussed new predictors identified for toxicity and early response in patients with MM on ide-cel.
The results suggest a possible treatment strategy of selinexor followed by immunotherapy.
The survey examined global access to 14 chemoimmunotherapy options and autologous stem cell transplant (ASCT).
Jens Hillengass, MD, PhD, covers updates from CARTITUDE that show cilta-cel is effective in early lines of therapy in MM.
Researchers point to the poor outcomes observed with existing treatments. Here's what they found.
Joshua Richter, MD, explained this finding and more results from the MyDRUG trial.
Rafael Renatino-Canevarolo, PhD, and colleagues explained just how the platform works.
Ola Landgren, MD, and colleagues presented details of the new clinical trial at the 65th ASH Annual Meeting and Exposition.
Cilta-cel improved survival outcomes compared with standard care in patients with lenalidomide-refractory multiple myeloma.
Carfilzomib improved PFS versus bortezomib in induction therapy regimens with lenalidomide and dexamethasone in MM.
Lenalidomide-associated ALL was seen in patients with MM, but discontinuation alone led to regression of clonal populations.
Patients with relapsed or refractory multiple myeloma sustained durable remissions after switching to biweekly teclistamab.
Dr. Coombs discussed the results from a survey of patients with myeloma and APPs who treat myeloma.
Elranatamab was effective and well-tolerated in patients with heavily pretreated relapsed or refractory multiple myeloma.
Of the 200 APPs surveyed, 72% reported being “generally knowledgeable” about MM before seeing their first patient.
Getting the right care team, treatment, and testing are three steps to empower patients with MM.
Clinicians weigh in on AI advances in hematological diagnoses, prognoses, and treatment.
Hematological cancer and death by hematological cancer was reduced in the group that had undergone bariatric surgery.
This episode of "Blood Cancer Talks" discusses the biology and management of multiple myeloma and the role of venetoclax.
The rate of grade 3-5 infections was 90% lower in MM patients receiving IV immunoglobulin than during the observation period.
The panel talks about the future of CAR-T: more targets, sequencing, and other patient considerations.
A study described several mutations and subclone events that appear to drive relapse in multiple myeloma.
Research suggests that "targeting FcRH5 with CAR T cells may represent a promising therapeutic avenue for MM.”
Researchers identified 1,055 patients diagnosed with MM from 2004 to 2018 who underwent AHSCT within a year of diagnosis.
Researchers conducted interviews to gather the perspectives of both clinicians and nurses.
The panel gives their opinions on vaccine strategies for patients with myeloma receiving bispecifics.
The panel discusses optimal dosing for teclistamab.
Dr. Martin asks Dr. Chari to provide insights on adverse event management with talquetamab.
The panel considers where CAR T-cell therapy should fit in the myeloma treatment paradigm.
The panel continues the conversation around toxicity management for bispecific agents.
The panel compares clinical trial and real-world data for CAR-Ts.
Dr. Fonseca offers his thoughts on the future of multiple myeloma treatment and more.
The panel discusses treatment-related side effects such as CRS, ICANS, and more.
Drs. Raje and Patel discuss how they decide between CAR-T and bispecifics for their myeloma patients.
The panel addresses side effects that are commonly seen in patients receiving bispecifics.
The panel discusses their personal experience with bispecifics-related REMS programs.
The panel discusses which patients may not be suitable for CAR T-cell therapy.
The panel discusses where they think bispecifics have "the best role" in the myeloma treatment paradigm.
The episode also highlights the S1211 study, which is the first randomized controlled trial with high-risk enrichment in MM.
Researchers conducted a cross-sectional survey of patients with multiple myeloma to address the question.
Dr. Richter discusses the data he presented during the 20th IMS Annual Meeting Exposition.
Researchers evaluated 1,704 patients with triple-class exposure, including 1,072 who had four-plus previous lines of therapy.
The panel discussed how CAR-T impacts myeloma standard of care.
The panel provided insights on how they determine whether to give a patient with myeloma CAR T-cell therapy or a bispecific.
The approval of the bispecific antibody is based upon data from the MonumenTAL-1 trial.
The phase III study included patients who received at least one prior line of therapy.
The researchers sought to assess the utility of MRD outside the context of clinical trials.
Daratumumab in combination with lenalidomide and dexamethasone provided greater OS in most subgroups.
Researchers and clinicians are attempting to make clinical trials better reflect the population of patients with MM.
The panel discussed the FDA-approved bispecific agents for myeloma and how the options performed in clinical trials.
In the first segment of the roundtable series, the panel discussed the latest CAR-T data, including KarMMa-3 and CARTITUDE-4.
Researchers examined tumor-intrinsic factors that promote multiple myeloma antigen escape.
Ajay Nooka, MD, FACP, discusses the data behind the FDA accelerated approval of elranatamab.
Dr. Nooka, who served as an investigator on the MagnetisMM-3 trial, discusses the impact of the accelerated approval.
CART-ddBCMA is an investigational new drug for the treatment of patients with relapsed or refractory multiple myeloma.
There was a median of two production slots per month from March 2021 to October 2021. All slots were filled.
The bispecific antibody received Breakthrough Therapy Designation from the FDA in November 2022.
There was no significant difference in the number of mutations present at diagnosis between the two groups of patients.
The researchers used a cumulative deficit approach to calculate a frailty index score at diagnosis and at landmark intervals.
It is approved as a weekly or biweekly subcutaneous injection after an initial step-up phase.
More than one-quarter of the patients required a dose reduction due to adverse events.
The US FDA and NMPA have approved IND applications for LBL-034 for the treatment of relapsed or refractory multiple myeloma.
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
In June 2023, a patient death led to the US Food and Drug Administration pausing the iMMagine-1 study.
Dr. Cerchione discusses the importance of ensuring adequate representation in multiple myeloma clinical trials.
Patients with clonal plasma cells in the autograft had a significantly lower MRD-negative CR rate after transplant.
The trial compared ciltacabtagene autoleucel with standard of care in patients with MM who were refractory to lenalidomide.
The supplemental BLA submission is supported by data from the CARTITUDE-4 study.
Researchers used a simulated partitioned survival model to compare overall survival among three treatment strategies.
A recent study showed significant differences in OS based on the t(4;14) translocation breakpoint area in MM.
The panelists highlight key data presented at ASCO 2023.
Toxicities such as cytokine release syndrome as they relate to BCMA bispecific antibodies for myeloma are discussed.
The panel discusses the new and emerging bispecific antibody treatment options for multiple myeloma.
The panel discusses data on the BCMA CAR-T construct PHE885 and the manufacturing needs that persist.
The panel discusses the real-world data and first-hand experience with the two FDA-approved CAR T-cell therapies for MM.
The hosts discuss the latest data on CAR-T from the summer conference season.
In this video interview from EHA, Dr, Munshi shares the close-out efficacy and safety results from CARTITUDE-1.
The panelists discuss their experience with CAR-T access challenges in the real-world clinical setting.
The panel discusses the FDA-approved BCMA-directed CAR-T options for multiple myeloma.
The panel discusses maintenance therapy options for early-relapsed multiple myeloma.
The FDA has put a clinical hold on the investigational new drug CART-ddBCMA.
Dr. Chari and the hosts also discuss a phase I trial of fixed-duration cevostamab, as well as a phase I trial of ABBV-383.
Dr. Martin discusses key updates in multiple myeloma from ASCO, EHA, and the IMWG meetings.
The panel considers triplet versus quadruplet therapy for myeloma induction.
The response rates seen with talquetamab in the trial were "very impressive," Dr. Schinke said.
Researchers are evaluating the combination to establish a recommended phase III dose for the first-line setting.
The study evaluated teclistamab in patients with relapsed or refractory multiple myeloma.
In the trial, patients received talquetamab at 0.4 mg/kg weekly or 0.8 mg/kg every two weeks.
The phase II study evaluated linvoseltamab, a bispecific antibody targeting BCMA and CD3, in relapsed or refractory MM.
Dr. Mohan discusses her 2023 ASCO Annual Meeting presentation with Chadi Nabhan, MD, MBA, FACP.
Patients treated with the higher dose had higher overall response rates.
Dr. Bansal and colleagues presented the results of the study at the 2023 ASCO Annual Meeting.
Approximately one-third of the heavily pretreated patients in the small study responded to therapy.
The overall response rate was 87.8% with 73% of patients achieving complete response.
The median time from last dose of selinexor to anti-BCMA therapy was eight weeks.
Improvement of nontarget lesions was noted in five of 25 patients (20%).
Health care disparities have been an "ongoing issue" for patients with cancer, especially in multiple myeloma.
At the ASCO meeting, researchers presented results of the trial with 22 months of follow-up.
The ongoing, long-term CARTITUDE study will continue to follow these patients for safety and survival.
Sikander Ailawadhi, MD, speaks about the Mayo Clinic's efforts to address health care disparities.
Researchers discuss how monitoring MRD in peripheral blood can aid in myeloma management.
Bone marrow assessment of MRD is “prognostic for survival”, but bone marrow remains hypocellular at month one after ...
A recent study suggests the initial T-cell landscape could shape responses to bispecific T-cell engagers in MM.
The study included patients from the National Cancer Research Institute Myeloma XI trial.
The researchers assigned points to multiple factors to develop a risk score.
A new study suggests there is an “optimal” dose of carfilzomib for patients with relapsed or refractory multiple myeloma.
The study was a retrospective pooled analysis of multicenter global clinical trials that submitted data to the US FDA.
The episode was inspired by an article titled “The Underrepresented Majority" by Andrés Gómez-De León, MD.
Dr. Gertz and the hosts provide an overview of risk-stratification approaches and clinical trials in smoldering MM.
Dr. Costa discusses the multiple uses of MRD in MM.
To quote a well-known exchange from the final Harry Potter movie, “it’s complicated.”
The FDA has set a target action date of December 16, 2023.
Sagar Lonial, MD, FACP, discusses how he approaches frontline therapy for multiple myeloma and key MRD considerations.
The panel advises on patient hand off to local care teams following CAR T-cell therapy for myeloma.
The panel discusses side effect management with CAR T-cell therapy.
This editorial outlines key practical points for the use of talquetamab in relapsed or refractory MM.
The panel addresses the choice between treating multiple myeloma with a bispecific agent or CAR T-cell therapy.
Drs. Martin and Voorhees discuss patient characteristics and populations that are suited for CAR-T therapy in myeloma.
The panel addresses the potential for frontline CAR-T use.
The panel debates whether CAR-T can be moved earlier in the course of myeloma treatment.
The panel discusses allogeneic CAR T-cell therapy and how it stacks up against autologous options.
Drs. Lonial and Martin discuss allogeneic, off-the-shelf CAR-T data.
BCMA-targeted autologous CAR T-cell therapies are discussed.
The panel discusses the second FDA-approved CAR-T therapy for myeloma, ciltacabtagene autoleucel.
Drs. Voorhees and Martin discuss one of the FDA-approved CAR-T therapies for myeloma, idecabtagene vicleucel.
In the first segment of the roundtable series, the panel discusses BCMA as an important target for treating multiple myeloma.
Dr. Tauro speaks about her presentation on novel strategies to overcome chemotherapy resistance in MM at AACR 2023.
The design of the bispecific antibody aims to overcome challenges with cytokine release syndrome.
The study used genomics to determine how often high-risk events "are missed at diagnosis and selected at relapse."
Novel agents did not significantly improve outcomes over conventional therapies in certain patients.
Novel targets are under investigation in several types of hematologic malignancies.
Dr. Wong hopes to see an expansion in the availability of new and novel treatments for myeloma.
The study included patients who had disease progression after participating in a bispecific antibody clinical trial.
Dr. Richard hopes that one day she can confidently tell patients facing a multiple myeloma diagnosis that there is a cure.
Novel therapies and “game-changing drugs” have made a major impact on the treatment of myeloma, Dr. Wong said.
Patients with clinical progression had a significantly shorter median OS from their first relapse.
Sandy Wong, MD, explains how clinicians and researchers can help educate others about myeloma.
Molly Stoddart, RN, BSN, is a clinical research nurse on the multiple myeloma team at the Winship Cancer Institute at Emory.
Around two-thirds of second primary malignancies were solid malignancies and 20% were myeloid malignancies.
Sandy Wong, MD, explains what Myeloma Awareness Month means to her as a clinician and a researcher.
The “greatest benefit" was observed in those who had t(4;14) or amp1q21.
Frailty measures have been "increasingly incorporated" in multiple myeloma trials in recent years.
Sagar Lonial, MD, FACP, Editor-in-Chief of Blood Cancers Today, discusses Multiple Myeloma Awareness Month.
Dr. Raje reflects on the mentors who shaped her career, the evolution of myeloma treatment, and more.
The four-year OS rate from the first randomization was 94% in patients without high-risk cytogenetic abnormalites.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Advertisement
Advertisement
Section Editor
Nisha Joseph, MDAssociate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.